Who else on the ASX joins Mesoblast in the fight against ARDS and where are they at?
Health & Biotech
Health & Biotech
Link copied to
ASX large cap biotech Mesoblast (ASX:MSB) is not alone in fighting Acute Respiratory Distress Syndrome (ARDS).
ARDS is a disease that hinders the lungs’ ability to operate and is a major culprit of COVID-19 deaths. Essentially it causes lungs to inflame and fill with fluid leaving patients struggling to breathe.
Mesoblast’s stem cell based Remestemcel-L product was intended to fight graft versus host disease but for several months has been put to the test against ARDS.
This has caused shares to rally for several months from $1.10 to as high as $5.50 in September.
Shares began to drop in October with the Pfizer vaccine news and the FDA ordering it to conduct another clinical trial in relation to treating bone marrow transplant complications.
The majority of ASX stocks in the fight against ARDS are biotechs although one exemption is medtech 4D Medical (ASX:4DX).
While XV has general focus on lung diseases, it has been validated to monitor ARDS as well as therapy and treatment research.
The company listed in August and is up 247 per cent since then.
Mesoblast’s fellow stem cell play Cynata Therapeutics (ASX:CYP) is another ASX candidate fighting ARDS.
It is currently recruiting for a clinical trial in New South Wales to test its Cymerus platform against ARDS.
However this is just one of many programs Cynata has going on. The most advanced is its fight against Graft vs Host disease where it is collaborating with Fujifilm.
Incannex Healthcare (ASX:IHL) is another, fighting ARDS with a therapy combining cannabidiol and hydroxychloroquine (IHL-675A).
Dimerix (ASX:DXB), which has traditionally targeted kidney disease had its DXB-200 drug chosen in June for a global program against ARDS.
Rounding out the list of ASX ARDS fighters is PharmAust (ASX:PAA) which, similar to Incannex, has passed in vitro studies and is looking to do clinical trials.
There are several other ASX stocks in the COVID-19 fight.
At Stockhead we tell it like it is. While Dimerix and Incannex are Stockhead advertisers, they did not sponsor this article.